116 related articles for article (PubMed ID: 37298855)
1. Inhibition of Mitochondrial Antioxidant Defense and CDK4/6 in Mesothelioma.
Kratzke M; Scaria G; Porter S; Kren B; Klein MA
Molecules; 2023 May; 28(11):. PubMed ID: 37298855
[TBL] [Abstract][Full Text] [Related]
2. Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
Bonelli MA; Digiacomo G; Fumarola C; Alfieri R; Quaini F; Falco A; Madeddu D; La Monica S; Cretella D; Ravelli A; Ulivi P; Tebaldi M; Calistri D; Delmonte A; Ampollini L; Carbognani P; Tiseo M; Cavazzoni A; Petronini PG
Neoplasia; 2017 Aug; 19(8):637-648. PubMed ID: 28704762
[TBL] [Abstract][Full Text] [Related]
3. Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells.
Bonelli M; Terenziani R; Zoppi S; Fumarola C; La Monica S; Cretella D; Alfieri R; Cavazzoni A; Digiacomo G; Galetti M; Petronini PG
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708306
[No Abstract] [Full Text] [Related]
4. Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition.
Paternot S; Raspé E; Meiller C; Tarabichi M; Assié JB; Libert F; Remmelink M; Bisteau X; Pauwels P; Blum Y; Le Stang N; Tabone-Eglinger S; Galateau-Sallé F; Blanquart C; Van Meerbeeck JP; Berghmans T; Jean D; Roger PP
Mol Oncol; 2024 Apr; 18(4):866-894. PubMed ID: 36453028
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma.
Aliagas E; Alay A; Martínez-Iniesta M; Hernández-Madrigal M; Cordero D; Gausachs M; Pros E; Saigí M; Busacca S; Sharkley AJ; Dawson A; Palmero R; Ruffinelli JC; Padrones S; Aso S; Escobar I; Ramos R; Llatjós R; Vidal A; Dorca E; Varela M; Sánchez-Céspedes M; Fennell D; Muñoz-Pinedo C; Villanueva A; Solé X; Nadal E
Br J Cancer; 2021 Nov; 125(10):1365-1376. PubMed ID: 34588615
[TBL] [Abstract][Full Text] [Related]
6. Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma.
Song X; Liu X; Wang H; Wang J; Qiao Y; Cigliano A; Utpatel K; Ribback S; Pilo MG; Serra M; Gordan JD; Che L; Zhang S; Cossu A; Porcu A; Pascale RM; Dombrowski F; Hu H; Calvisi DF; Evert M; Chen X
Clin Cancer Res; 2019 Jan; 25(1):403-413. PubMed ID: 30084835
[TBL] [Abstract][Full Text] [Related]
7. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
Kanteti R; Riehm JJ; Dhanasingh I; Lennon FE; Mirzapoiazova T; Mambetsariev B; Kindler HL; Salgia R
Sci Rep; 2016 Sep; 6():32992. PubMed ID: 27623107
[TBL] [Abstract][Full Text] [Related]
8. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
Kishino E; Ogata R; Saitoh W; Koike Y; Ohta Y; Kanomata N; Kurebayashi J
Breast Cancer; 2020 May; 27(3):415-425. PubMed ID: 31823286
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.
Schelch K; Hoda MA; Klikovits T; Münzker J; Ghanim B; Wagner C; Garay T; Laszlo V; Setinek U; Dome B; Filipits M; Pirker C; Heffeter P; Selzer E; Tovari J; Torok S; Kenessey I; Holzmann K; Grasl-Kraupp B; Marian B; Klepetko W; Berger W; Hegedus B; Grusch M
Am J Respir Crit Care Med; 2014 Oct; 190(7):763-72. PubMed ID: 25188816
[TBL] [Abstract][Full Text] [Related]
10. Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer.
Long Q; Ma AH; Zhang H; Cao Z; Xia R; Lin TY; Sonpavde GP; de Vere White R; Guo J; Pan CX
Cancer Immunol Immunother; 2020 Nov; 69(11):2305-2317. PubMed ID: 32506263
[TBL] [Abstract][Full Text] [Related]
11. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
12. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
[TBL] [Abstract][Full Text] [Related]
13. CDK4 and CDK5 Inhibition Have Comparable Mild Hypothermia Effects in Preventing Drp1-Dependent Mitochondrial Fission and Neuron Death Induced by MPP
Yang SH; Huang CY; Hsieh CY; Chuang JI
Mol Neurobiol; 2020 Oct; 57(10):4090-4105. PubMed ID: 32666227
[TBL] [Abstract][Full Text] [Related]
14. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
15. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A
Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562
[TBL] [Abstract][Full Text] [Related]
16. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
[TBL] [Abstract][Full Text] [Related]
17. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1
Schneeweiss-Gleixner M; Byrgazov K; Stefanzl G; Berger D; Eisenwort G; Lucini CB; Herndlhofer S; Preuner S; Obrova K; Pusic P; Witzeneder N; Greiner G; Hoermann G; Sperr WR; Lion T; Deininger M; Valent P; Gleixner KV
EBioMedicine; 2019 Dec; 50():111-121. PubMed ID: 31761618
[TBL] [Abstract][Full Text] [Related]
18. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
19. CDK4/6 Inhibition Shows Clinical Activity in p16ink4A-Deficient Mesothelioma.
Cancer Discov; 2022 Apr; 12(4):885. PubMed ID: 35373278
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.
Ouyang Z; Wang S; Zeng M; Li Z; Zhang Q; Wang W; Liu T
Cell Commun Signal; 2019 Feb; 17(1):17. PubMed ID: 30808351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]